Ignite Creation Date:
2024-05-06 @ 8:25 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06376084
Status:
RECRUITING
Last Update Posted:
2024-04-19
First Post:
2024-04-17
Brief Title:
Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC
Sponsor:
Organization:
AstraZeneca